Trastuzumab deruxtecan (Enhertu®) is used to treat certain secondary breast cancers. This blog delves into the science while looking at the real experience of a patient on this drug.
Daiichi Sankyo announces the availability of ENHERTU (fam-trastuzumab deruxtecan-nxki) in the U.S.
Trastuzumab deruxtecan (Enhertu®) is used to treat certain secondary breast cancers. This blog delves into the science while looking at the real experience of a patient on this drug.
On April 5, 2024, the FDA approved ENHERTU to treat HER2-positive solid tumors in adults who have received previous systemic treatment
ENHERTU has now received approval for three tumor types and it is expected to transform the HER2+ Cancer treatment outlook.
Enhertu is a targeted therapy that drug treats HER2-low breast cancer. Here's what to know about how Enhertu works, its side effects, and more.
Enhertu è pronto a diventare il primo ADC con targeting HER2 tumore-agnostico / Enhertu Poised to Become First Tumor-Agnostic HER2-Targe...
Metastatic breast cancer remains incurable, but researchers’ understanding of the disease is leading to additional treatments.
Research also showed that treatment before surgery benefits patients with HER2-low breast cancer.
AstraZeneca spune că un studiu în fază avansată confirmă beneficiile medicamentului Enhertu pentru cancerul de sân la pacientele cu o formă avansată a bolii care au primit anterior un alt tratament.
In our third blog with Make2ndsCount, we'll be looking in depth at current and future treatments for HER2 secondary breast cancer patients.
Cancer therapy is getting a shot in the arm. Drug giants like AstraZeneca and Sanofi are placing bets on drugs that target tumours directly and have few side effects. With a potential $60 billion in annual revenue up for grabs, competition will be fierce.
#Walker
